Future analyses are planned, including characterization of the spatial relationships between effector (CD8+) and suppressive (FoxP3+ or PD-L1+) cell subsets across the various tumor types and correlations with clinical outcomes, such as tumor recurrence. The gene discussed is CD274; the disease is neoplasm.